• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Alcon receives two Frost & Sullivan awards in 2005


Frost & Sullivan recognized Alcon Inc., with the Product of the Year and the Company of the Year awards for 2005.

The product award was for the AcrySof ReSTOR multifocal IOL. "The lens truly represents a new paradigm in cataract surgery, which will provide the nearly 3 million people in the United States who have cataract surgery each year with the option for a new standard of care and improved vision," said Frost & Sullivan research analyst Mansi Kothari, PhD.

The analyst firm said that AcrySof ReSTOR is unlike other advanced IOLs because the product combines apodization, diffraction, and refraction, thereby circumventing the dependence on eye muscles for accommodation. Clinical trials show 80% of patients never wore glasses or bifocals after surgery.

The company award recognizes Alcon's growing market penetration, satisfaction among prescribers and patients, and successful market strategy and employee satisfaction in the ocular hypertension and open angle glaucoma market as well.

"A 2005 Frost & Sullivan survey showed Alcon as the most respected company by ophthalmologists and optometrists in the U.S. glaucoma medication market due to its excellence in first-line glaucoma medication, and its dedication in facilitating access to medication for non-insured patients through coupons, samples, and concise needy-patient forms for physicians," said Dhiraj Ajmani, another Frost & Sullivan research analyst.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.